US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback